CiTOS
Research interests at CiTOS are at the interface between organic chemistry and chemical engineering. Current active research areas include methodology continuous flow organic synthesis, pharmaceutical development and upgrading of biosourced platform molecules. CiTOS is the first Corning Incorporated Advanced-Flow™ reactor (AFR) Qualified Lab in Europe.
T
he scope aims developing technologies and methods under continuous flow conditions for:
- Enabling process conditions considered as demanding, hazardous or difficult to achieve in conventional batch setups
- Reactions involving rapidly decaying molecules, unstable and dangerous intermediates
- Complex sequences of reactions
- Improving process safety and efficiency
- Decreasing process space and time frames
The lab develops integrated and scalable continuous flow strategies for the manufacturing of active pharmaceuticals. Our research efforts aim at providing new strategies for known active pharmaceuticals as well as at designing new concepts for the continuous flow manufacturing of emerging pharmaceuticals such as peptides. The lab is licensed for the manufacturing of Schedule I-V substances. The lab is also active in biomass valorization. Our research efforts aim at providing integrated and scalable continuous flow strategies for the upgrading of biosourced platform molecules toward industrially relevant building blocks.
CONTACT : Dr. J.-C. Monbaliu
